Revusiran

Drug Profile

Revusiran

Alternative Names: ALN-TTRsc; SAR438714; siTTRsc

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Alnylam Pharmaceuticals
  • Class Heart failure therapies; Small interfering RNA
  • Mechanism of Action Prealbumin inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyloidosis
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Amyloid polyneuropathy; Cardiomyopathies

Most Recent Events

  • 08 Feb 2017 Alnylam Pharmaceuticals terminates a phase III extension trial for familial amyloidotic Cardiomyopathy (In the elderly, In adults) due to safety findings in United Kingdom (SC) (EudraCT2015-005333-49)
  • 01 Nov 2016 Alnylamt terminates a phase III trial in Cardiomyopathy (In adults, In the elderly) due to unacceptable risk benefit profile in USA, United Kingdom, Belgium, Canada, France, Germany, Italy, Sweden and Spain (SC) (NCT02319005)
  • 07 Oct 2016 Discontinued - Phase-II for Amyloid polyneuropathy in United Kingdom, Sweden, Portugal, Germany, France (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top